StreetInsider.com News Articles

Form 6-K Enlivex Ltd. For: Oct 22

Thu, 22 Oct 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20261022/27223524.html

Enlivex to execute 1-for-16 reverse share split on Oct. 27

Thu, 22 Oct 2026 17:16:28 -0400

Enlivex Ltd. (Nasdaq: ENLV) announced a 1-for-16 reverse split of its ordinary shares, set to take effect October 27, 2026, after which the shares will trade on the Nasdaq Capital Market on a split-adjusted basis.

Under the terms of the reverse split, every 16 ordinary shares will be automatically combined into one ordinary share. The number of authorized ordinary shares will be reduced from 158,333,333 to 9,895,833, and the par value per share will increase from NIS 6.00 to NIS 96.00.

The number of issued and outstanding ordinary shares will decrease from 24,511,905 to approximately 1,531,995, subject to adjustment for fractional share

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

Thu, 22 Oct 2026 17:16:00 -0400

Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the “Reverse Split”) of its ordinary shares, which will become effective on October 27, 2026, on which date the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis.

As a result of the Reverse Split, every 16 ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

Thu, 22 Oct 2026 17:16:00 -0400

As a result of the Reverse Split, every 16 ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares

Form 6-K Enlivex Ltd. For: Oct 19

Mon, 19 Oct 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20261019/27201108.html

Enlivex cuts 60% of workforce to focus on knee OA trial

Mon, 19 Oct 2026 08:17:11 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced a cost reduction plan, effective immediately, that includes cutting approximately 60% of its workforce and winding down all research and development activities not related to its Phase 2b clinical trial of Allocetra™ for knee osteoarthritis.

Management salaries will be reduced by 20%, while Chief Executive Officer Dr. Oren Hershkovitz will take a 40% pay cut. The Israel-based company said the measures are designed to reduce cash burn and concentrate resources on the Phase 2b trial.

The Phase 2b trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating intra-articular injections of Allocetra™ in patients aged 64 and

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Mon, 19 Oct 2026 08:17:00 -0400

Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial
Workforce reduced by approximately 60%; management and CEO salaries reduced
Plan designed to substantially reduce cash burn
Topline Phase 2b six-month endpoint data expected by mid-2027

Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a cost reduction plan, effective immediately, designed to substantially reduce the Company's cash burn and focus

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Mon, 19 Oct 2026 08:17:00 -0400

Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial
Workforce reduced by approximately 60%; management and CEO salaries reduced
Plan designed to substantially reduce cash burn
Topline Phase 2b six-month endpoint data expected by mid-2027

Form 6-K/A Enlivex Ltd. For: Oct 02

Fri, 02 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261002/27142424.html

Form 6-K/A Enlivex Ltd. For: Sep 30

Thu, 01 Oct 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27130542.html

Form 6-K Enlivex Ltd. For: Sep 29

Tue, 29 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260929/27123382.html

Form 6-K Enlivex Ltd. For: Jun 30

Fri, 25 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260925/27107590.html

Form 6-K Enlivex Ltd. For: Sep 22

Tue, 22 Sep 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260922/27087955.html

Enlivex terminates share sale deal with Rain Foundation

Tue, 22 Sep 2026 08:00:57 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced the termination of a securities purchase agreement it had previously entered into with the Rain Foundation, according to a press release dated Sept. 22, 2026.

Under the agreement, Enlivex had agreed, subject to shareholder approval, to sell and issue 66,666,667 ordinary shares to the Rain Foundation in a private placement. The Rain Foundation had elected to purchase the shares using RAIN tokens.

Enlivex said it terminated the agreement in accordance with its termination rights under the contract. As a result, the company will not proceed with the private placement and will not seek shareholder approval in connection

Enlivex terminates share sale deal with Rain Foundation

Tue, 22 Sep 2026 08:00:57 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced the termination of a securities purchase agreement it had previously entered into with the Rain Foundation, according to a press release dated Sept. 22, 2026.

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

Tue, 22 Sep 2026 08:00:00 -0400

Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a securities purchase agreement entered into with the Rain Foundation, pursuant to which the Company had agreed, subject to shareholder approval, to sell and issue to the Rain Foundation in a private placement an aggregate of 66,666,667 of the Company’s ordinary shares, which the investor had elected to purchase using RAIN tokens.

The Company terminated the securities purchase agreement in accordance with the Company’s termination

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

Tue, 22 Sep 2026 08:00:00 -0400

The Company terminated the securities purchase agreement in accordance with the Company’s termination

Form 424B3 Enlivex Ltd.

Mon, 17 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26934305.html

Form 424B3 Enlivex Ltd.

Mon, 17 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26934305.html

Form EFFECT Enlivex Ltd.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924080.html

Form EFFECT Enlivex Ltd.

Fri, 14 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26924080.html

Form SCHEDULE 13G Enlivex Ltd. Filed by: Lind Partners LLC

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920698.html

Form SCHEDULE 13G Enlivex Ltd. Filed by: Lind Partners LLC

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920698.html

Form 6-K Enlivex Ltd. For: Aug 11

Tue, 11 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26905919.html

Form 6-K Enlivex Ltd. For: Aug 11

Tue, 11 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260811/26905919.html